Finance

Beta
Lists
VCEL:NASDAQ
Vericel Corp
$36.30
+1.71%
(+0.61) 1D
$36.30
0.00% (0.00)
After hours
Closed: Jun 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VCEL...
Open
$35.73
High
$36.91
Low
$35.73
Mkt. cap
1.85B
Avg. vol.
654.16K
Volume
558.32K
P/E ratio
99.58
52-wk high
$45.97
52-wk low
$28.95
EPS
$0.36
Beta
1.12
Shares outstanding
51.07M
No. of employees
398
Open
$35.73
High
$36.91
Low
$35.73
Mkt. cap
1.85B
Avg. vol.
654.16K
Volume
558.32K
P/E ratio
99.58
52-wk high
$45.97
52-wk low
$28.95
EPS
$0.36
Beta
1.12
Shares outstanding
51.07M
No. of employees
398
Analyst outlook
Analyst Ratings
Based on 5 analysts giving stock ratings to VCEL in the past 3 months
Strong Buy
Buy
4
Hold
1
Sell
0
12 month forecast
Based on 5 Wall Street analysts offering 12 month price targets for VCEL in the last 3 months.
Highest
Current $36.30
$70.00 (+92.84%)
Average
$61.00 (+68.04%)
Lowest
$55.00 (+51.52%)
News stories
From sources across the web
Profile
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan. In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before. In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts. Wikipedia
About Vericel Corp
CEONick Colangelo
Employees398
Founded1989
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitevcel.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
63.24M
67.50M
92.92M
68.42M
Cost of goods sold
16.63M
17.92M
19.79M
19.16M
Cost of revenue
16.63M
17.92M
19.79M
19.16M
Research and development expenses
6.73M
6.32M
7.25M
8.10M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
41.91M
39.82M
43.46M
49.23M
Operating expense
48.64M
46.14M
50.71M
57.33M
Total operating expenses
65.27M
64.05M
70.50M
76.49M
Operating income
-2.03M
3.45M
22.42M
-8.06M
Other non operating income
-24.00K
-26.00K
-36.00K
71.00K
EBT including unusual items
-553.00K
5.07M
24.10M
-6.30M
EBT excluding unusual items
-553.00K
5.07M
24.10M
-6.30M
Income tax expense
-
-
859.00K
-
Effective tax rate
-
-
3.56%
-
Other operating expenses
-
-
-
-
Net income
-553.00K
5.07M
23.24M
-6.30M
Net profit margin
-0.87%
7.52%
25.01%
-9.21%
Earnings per share
-0.01
0.10
0.45
-0.12
Interest and investment income
1.66M
1.81M
1.88M
1.85M
Interest expense
-157.00K
-158.00K
-162.00K
-160.00K
Net interest expenses
1.50M
1.65M
1.72M
1.69M
Depreciation and amortization charges
-
-
-
-
EBITDA
797.00K
6.39M
25.50M
-4.80M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer